Bayzed Health Group (HKSE:02609) Research & Development: HK$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02609 Bayzed Health Group Inc HKSE:02609
12 GF Score
Price HK$2.99
! 2 Warning Signs
View Full Analysis

What is Bayzed Health Group Research & Development?

Bayzed Health Group HKSE:02609 -1.81% 12 Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus rates HKSE:02609 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bayzed Health Group's Research & Development for the six months ended in Dec. 2025 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0 Mil.

Bayzed Health Group  (HKSE:02609) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bayzed Health Group Research & Development Related Terms

Bayzed Health Group Research & Development Historical Data

* Premium members only.

The historical data trend for Bayzed Health Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayzed Health Group Research & Development Chart

Bayzed Health Group Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00 0.00 0.00

Bayzed Health Group Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
HKSE:02609
12GF Score
Bayzed Health Group Inc HKSE:02609
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayzed Health Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0 Mil mean?
Bayzed Health Group (HKSE:02609) has a Research & Development of HK$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Bayzed Health Group and its competitors.
Is Bayzed Health Group's Research & Development too high?
Bayzed Health Group's current Research & Development is HK$0 Mil. Overall, Bayzed Health Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bayzed Health Group's Research & Development compare to HCA and THC?
Bayzed Health Group's Research & Development of HK$0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bayzed Health Group and its competitors. Bayzed Health Group's current Research & Development is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayzed Health Group stock overvalued right now?
Bayzed Health Group (HKSE:02609) has a current Research & Development of HK$0 Mil. The current Research & Development is HK$0 Mil. Bayzed Health Group's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bayzed Health Group (HKSE:02609), the current Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bayzed Health Group Business Description

Address No. 16 Lize Road, Room 2401, Mingfeng Tower Office Building, Fengtai District, Beijing, CHN
Bayzed Health Group Inc is an oncology healthcare group that principally engages in the investment in, and provision of, medical and healthcare related services in the PRC. It operates and manages a network of eight hospitals in Beijing, Tianjin, Shanxi Province, Anhui Province, and Henan Province, with a strategic focus on the provision of full-cycle oncology healthcare services through its direct ownership of the equity interest in six private for-profit hospitals and management over two private not-for-profit hospitals.
12GF Score

Get the complete analysis for HKSE:02609

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.99
Price